Joshua Bauml, MD

Today we mark an important moment for the head and neck cancer community. This approval reflects what’s possible when research, clinical care and the patient community come together.

jnj.com/media-center/p…

FDA Priority Review has been granted for a potential new treatment option in recurrent or metastatic head & neck cancer. Building on progress in lung cancer, we're advancing innovation for patients with unmet needs. #Oncology ow.ly/RLX850ZuJpB

Treatment for #LungCancer touches every part of a person’s life. With a subcutaneous therapy available for #NSCLC, we’re continuing to rethink how care is delivered, with patients and care teams in mind. Read more: bit.ly/4bnKo3S

#JNJOncology #MyCompany

Head and neck cancer can be relentless. Even after treatment, many people see it return or continue to progress.

@JNJInnovMed's data at #ASCO26 focused on expanding options for these patients & supported our recent FDA filing. Learn more:

bit.ly/43GtZ6i

This #HeadAndNeckCancerAwareness Month, @hncalliance held a Move-a-Thon & colleagues across @JNJInnovMed joined in.

I carried the spirit of moving on behalf of patients on a run while traveling in Asia.

Awareness, movement & solidarity matter everywhere & every month.